Ihr Broker

  • DAX 0,70
  • EUR/USD 0,50
  • GOLD 0,30

Nur Spreads

Keine Kommission

Jetzt registrieren

CFDs sind komplexe Instrumente und umfassen aufgrund der Hebelfinanzierung ein hohes Risiko, schnell Geld zu verlieren.

PreveCeutical Medical Inc., CA74141E1043

PreveCeutical Medical Inc., CA74141E1043

14.01.2020 - 14:02:40

PreveCeutical Announces Further Updates to the Successful Engineering & Cell-Based Efficacy Screening of its Smart-siRNA Constructs for its Dual Gene Therapy Research Program

DGAP-News: PreveCeutical Medical Inc.

/ Key word(s): Miscellaneous

PreveCeutical Announces Further Updates to the Successful Engineering & Cell-Based Efficacy Screening of its Smart-siRNA Constructs for its Dual Gene Therapy Research Program

14.01.2020 / 14:00

The issuer is solely responsible for the content of this announcement.

14.01.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

Language: English Company: PreveCeutical Medical Inc.

Canada ISIN: CA74141E1043 EQS News ID: 953065   End of News DGAP News Service

953065  14.01.2020 

@ dgap.de